Scope Management in Drug Development: When Science Changes the Plan

Introduction

Science rarely cooperates with project plans. This is not a criticism of drug development — it is the nature of the work. Hypotheses are tested, data surprises, regulators weigh in, and the path forward shifts. But there is a significant difference between expected change in a scientific program and uncontrolled scope expansion that quietly consumes timelines, budgets, and organizational focus. In drug development, that distinction does not always get the attention it deserves.

Scope creep — the uncontrolled expansion of project requirements beyond the original plan — is one of the most common risks in project management, affecting projects across industries, sizes, and levels of complexity (link). In biotech and pharma, it wears a distinctive uniform: a new biomarker added to a Phase II trial, an exploratory endpoint folded into a pivotal study, a manufacturing process adjustment that ripples into a regulatory submission. Each change seems reasonable in isolation. Together, they destabilize programs that were already operating at the edge of capacity.

This post explores what rigorous scope management actually looks like in a drug development context — and why the answer is not to resist scientific evolution, but to govern it.

Laboratory bench showing tools and notes used in drug development

The Scope Baseline and the Fourth Constraint

The Project Management Body of Knowledge (PMBOK) Guide defines the scope baseline as the approved version of the project's formal scope documents — comprising the project scope statement, the Work Breakdown Structure (WBS), and its associated WBS dictionary — that can only be modified through formal change control procedures. It is not simply a record of what was planned. It is the mechanism by which the project team, sponsor, and stakeholders maintain a shared and enforceable definition of the project's boundaries.

In most industries, projects are bounded by the classic triple constraint: time, cost, and scope. Drug development introduces a fourth, non-negotiable constraint: regulatory compliance. An IND-enabling package has defined contents. A clinical protocol, once approved by an IRB or ethics committee, carries legal and ethical obligations. An NDA or BLA submission is governed by explicit regulatory requirements. These are not negotiable scope elements — they are the floor beneath which no change control system can reach. Any scope management framework in life sciences must treat regulatory requirements as fixed inputs to the scope baseline, not variables to be negotiated.

This fourth constraint does not make scope management harder so much as it clarifies the stakes. Undocumented scope changes in a GxP environment are not just project management failures — they are potential compliance failures. Every change to a validated process, a clinical protocol, or a regulatory submission strategy must pass through a documented, traceable review before it is implemented.

The Protocol Amendment: Scope Creep with an IRB Stamp

The single most pervasive form of scope change in clinical drug development is the protocol amendment. And the data on how frequently it occurs is sobering. A 2022 Tufts Center for the Study of Drug Development (Tufts CSDD) follow-up study, which analyzed data from 950 protocols and 2,188 amendments, found that the prevalence of protocols with at least one amendment in Phases I–IV has increased substantially — from 57% to 76% — and the mean number of amendments per protocol has increased 60%, to 3.3, up from 2.1 in 2015 (link).

The cost and time consequences are equally significant. Tufts CSDD research found the median direct cost to implement a substantial amendment was $141,000 for a Phase II protocol and $535,000 for a Phase III protocol (link). The total average time to implement an amendment has nearly tripled during the past decade, with the time from identifying the need to final ethics committee approval now averaging 260 days — and the average duration during which investigative sites operate under different protocol versions spanning 215 days (link).

The often-uncomfortable truth is that not all of this is unavoidable. Approximately one-third of all amendments have been deemed partially or completely avoidable, with undetected design flaws, protocol inconsistencies, and difficulties recruiting study volunteers rated among the causes that sponsors could have better anticipated (link).

From a project management standpoint, avoidable amendments are a scope management failure. They represent scope decisions — adding endpoints, adjusting eligibility criteria, modifying assessment schedules — that were made informally or prematurely and then corrected mid-execution. The "scope creep by scientific curiosity" problem is particularly acute in research-oriented organizations where the impulse to collect more data is strong and the downstream operational cost of that impulse is underestimated.

The WBS as a Scope Defense Tool

One of the most underutilized scope management instruments in drug development is the Work Breakdown Structure. The WBS is not a Gantt chart. It is not a high-level project timeline. It is a hierarchical decomposition of all the work required to achieve a project's objectives — broken down to the level of individual work packages that can be assigned, tracked, estimated, and governed. In the PMBOK framework, the WBS together with the project scope statement and WBS dictionary constitutes the scope baseline.

In clinical programs, a well-constructed WBS makes scope creep visible before it becomes embedded. When a scientific team proposes adding an exploratory endpoint, a WBS-grounded review immediately surfaces the downstream implications across multiple work packages:

• Additional CRF pages and EDC system build, validation, and reprogramming

• Data management and biostatistics plan updates, including revised Tables, Listings, and Figures

• Site retraining and investigator meeting requirements

• IRB/ethics committee amendment submission and approval cycles

• Potential patient reconsent, which must be completed before amended procedures begin

  
  

Without the WBS, these implications are invisible until they surface as delays. With it, they become a structured impact assessment that the project sponsor and change control board can evaluate before a decision is made. This aligns with the Ganvion 6-stage small molecule development framework (link), in which decisions are structured as work packages and criteria as activities — not informal discussions that happen in the margins of a team meeting. Every proposed change to a program's scope should be evaluated against what it actually adds to the WBS, what it costs, and what it displaces.

Change Control in a GxP Environment

In a GxP-regulated environment, change control is not just a project management discipline — it is a compliance requirement. Every modification to a validated system, an approved protocol, or a regulatory filing strategy must be formally documented, assessed for impact, reviewed, and approved before implementation. The PMBOK establishes the change management plan as a core component of the project management plan, defining the change control board (CCB), its authority, and the process by which change requests are submitted, evaluated, and dispositioned.

In practice, biotech and pharma project managers need to ensure that their project-level change control processes are integrated with — not separate from — the organization's broader quality management systems. A protocol amendment is simultaneously a project scope change and a GCP compliance event. A change to an IMP release specification is simultaneously a project change and a GMP quality event. Operating these processes in separate silos creates documentation gaps that regulators notice and that auditors flag.

For organizations at lower tiers of PMO maturity — particularly the ad hoc or informal tiers described in Ganvion's 4-tier PMO maturity model (link) — the absence of integrated change control is one of the most consequential gaps. Teams may have a quality change control system managed by regulatory affairs or QA, and a project management plan maintained in a spreadsheet, with no formal linkage between them. When a scope change occurs, one system captures it as a compliance record while the other never reflects it at all, leaving the project team operating on different versions of reality.

The PMBOK requires that every change request — regardless of origin — be formally evaluated for impact before a disposition decision is made. In a drug development program, that evaluation must address:

• Impact on the scope, schedule, cost, and quality baselines

• Whether the change triggers a protocol amendment or IRB notification

• Whether it affects an existing regulatory commitment or submission strategy

• Whether it requires updates to validated systems under GxP requirements

• Whether the change aligns with — or creates risk to — the project's approved business case

  
  

These are not afterthoughts. They are standard elements of a change impact assessment in a regulated environment.

Tracing Scope Changes Back to the Business Case

There is a final discipline that separates reactive scope management from genuinely strategic scope governance: the requirement to link every proposed change back to the project's business case and benefits realization plan. This is not bureaucracy — it is the mechanism by which organizations ask the right question before approving a change: does this modification still move us toward the value we committed to delivering, or does it dilute it?

Adding an exploratory endpoint may generate interesting science. But if it extends the trial by four months, increases the per-patient cost, and delays the primary endpoint readout that investors and regulatory reviewers are waiting for, it is a scope change that may be scientifically defensible but commercially harmful. Forcing that analysis through a structured change control process — one that explicitly evaluates the change against the approved business case — gives leadership the information they need to make an informed decision rather than an instinctive one.

The benefits register, introduced in the benefits realization framework discussed in a previous Ganvion post (link), is a useful anchor here. If the program's expected benefits are documented with clear measurement criteria, any proposed scope change can be evaluated against a single governing question: does this change support, threaten, or have no impact on the benefits we committed to delivering? That question alone filters out a significant portion of scope additions that would otherwise proceed on the strength of scientific enthusiasm rather than strategic logic.

Conclusion

Science will always change the plan. That is not a problem to be eliminated — it is a reality to be managed. The difference between programs that absorb change constructively and those that are destabilized by it is not scientific certainty. It is the presence or absence of a disciplined scope management infrastructure: a defined baseline, a functional WBS, an integrated change control process, and the organizational habit of evaluating every proposed change against the business case before approving it.

At Ganvion Biotech Solutions, we help life sciences organizations build the scope governance frameworks that keep programs on track without suppressing scientific judgment. Whether your team is navigating a first-in-human study with a lean staff or managing a multi-asset portfolio across multiple functional groups, we can help you design the processes that make change manageable — and expensive surprises avoidable.